Reported Earnings • May 11
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: US$0.014 (up from US$0.12 loss in FY 2024). Revenue: US$11.7m (up 140% from FY 2024). Net income: US$334.0k (up US$3.06m from FY 2024). Profit margin: 2.8% (up from net loss in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.3%. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. New Risk • Apr 05
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (US$3.1m revenue). Market cap is less than US$100m (UK£10.8m market cap, or US$14.3m). New Risk • Jan 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (US$3.1m revenue). Market cap is less than US$100m (UK£8.16m market cap, or US$11.0m). Breakeven Date Change • Dec 31
No longer forecast to breakeven The analyst covering MYCELX Technologies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$200.0k in 2025. New forecast suggests the company will make a loss of US$700.0k in 2026. Reported Earnings • Sep 21
First half 2025 earnings released: US$0.079 loss per share (vs US$0.059 loss in 1H 2024) First half 2025 results: US$0.079 loss per share (further deteriorated from US$0.059 loss in 1H 2024). Revenue: US$1.67m (down 52% from 1H 2024). Net loss: US$1.92m (loss widened 41% from 1H 2024). Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. New Risk • Sep 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$3.3m Forecast net loss in 1 year: US$145k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.73m market cap, or US$7.81m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Currently unprofitable and not forecast to become profitable next year (US$145k net loss next year). Revenue is less than US$5m (US$3.1m revenue). Breakeven Date Change • Sep 17
Forecast to breakeven in 2025 The analyst covering MYCELX Technologies expects the company to break even for the first time. New forecast suggests the company will make a profit of US$400.0k in 2025. Earnings growth of 79% is required to achieve expected profit on schedule. Annuncio • Jun 10
MYCELX Technologies Corporation, Annual General Meeting, Sep 23, 2025 MYCELX Technologies Corporation, Annual General Meeting, Sep 23, 2025. Location: the offices of cavendish capital markets limited, one bartholomew close, ec1a 7bl, london United Kingdom New Risk • May 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.36m market cap, or US$7.11m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (US$4.9m revenue). Reported Earnings • May 13
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: US$0.12 loss per share (improved from US$0.16 loss in FY 2023). Revenue: US$4.90m (down 55% from FY 2023). Net loss: US$2.72m (loss narrowed 27% from FY 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. New Risk • Apr 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.73m market cap, or US$7.49m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (US$356k net loss in 2 years). Annuncio • Apr 08
Mycelx Technologies Corporation Updates Earnings Guidance for 2025 MYCELX Technologies Corporation updated earnings guidance for 2025. For the year the company announced that Given the uncertainty created by the tariff program, which management will continue to monitor, projects have quoted but not signed must be requoted for customer approvals, which could potentially impact project and delivery timelines later in the year. In recognition of the difficult forecast environment, the Company is revising Fiscal Year 2025 revenue to be between $12.5 million and $15.5 million. The wide range reflects the size of the projects in the forecast and project pipeline. The Company will be profitable at the lower end of the range with inclusion of the gain on the Saudi asset sale. New Risk • Jan 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.92m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Market cap is less than US$10m (UK£7.92m market cap, or US$9.89m). Annuncio • Jan 06
Mycelx Technologies Corporation Provides Earnings Guidance for the Year 2024 MYCELX Technologies Corporation provided earnings guidance for the Year 2024. The Company expects its 2024 year-end revenue to be c.a. $4.9 million. New Risk • Nov 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (UK£8.91m market cap, or US$11.5m). Reported Earnings • Sep 27
First half 2024 earnings released: US$0.059 loss per share (vs US$0.065 loss in 1H 2023) First half 2024 results: US$0.059 loss per share (improved from US$0.065 loss in 1H 2023). Revenue: US$3.50m (down 37% from 1H 2023). Net loss: US$1.36m (loss narrowed 9.6% from 1H 2023). Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat. Annuncio • Aug 31
MYCELX Technologies Corporation has completed a Follow-on Equity Offering in the amount of £0.711108 million. MYCELX Technologies Corporation has completed a Follow-on Equity Offering in the amount of £0.711108 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 985,957
Price\Range: £0.515
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 346,292
Price\Range: £0.515
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 48,543
Price\Range: £0.515
Transaction Features: Regulation S; Subsequent Direct Listing New Risk • Aug 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Market cap is less than US$100m (UK£12.5m market cap, or US$16.5m). Annuncio • Jun 06
MYCELX Technologies Corporation, Annual General Meeting, Jul 09, 2024 MYCELX Technologies Corporation, Annual General Meeting, Jul 09, 2024. Location: the offices of canaccord genuity, 88 wood st, ec2v 7qr, london United Kingdom Reported Earnings • May 17
Full year 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in FY 2022) Full year 2023 results: US$0.16 loss per share (improved from US$0.18 loss in FY 2022). Revenue: US$10.9m (up 8.8% from FY 2022). Net loss: US$3.71m (loss narrowed 7.1% from FY 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • Apr 07
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (UK£11.6m market cap, or US$14.7m). Annuncio • Feb 22
MYCELX Technologies Corporation Provides Earnings Guidance for the Year 2024 MYCELX Technologies Corporation provided earnings guidance for the year 2024. The company is revising its forecasted revenue for 2024, which is now expected to be in the range of $9.0 million to $10.0 million. Reported Earnings • Sep 21
First half 2023 earnings released: US$0.065 loss per share (vs US$0.13 loss in 1H 2022) First half 2023 results: US$0.065 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$5.57m (up 51% from 1H 2022). Net loss: US$1.51m (loss narrowed 48% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Jun 21
MYCELX Technologies Corporation, Annual General Meeting, Sep 26, 2023 MYCELX Technologies Corporation, Annual General Meeting, Sep 26, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Canaccord Genuity, 88 Wood St, London EC2V 7QR London United Kingdom Reported Earnings • May 18
Full year 2022 earnings released: US$0.18 loss per share (vs US$0.073 loss in FY 2021) Full year 2022 results: US$0.18 loss per share (further deteriorated from US$0.073 loss in FY 2021). Revenue: US$10.0m (up 18% from FY 2021). Net loss: US$3.99m (loss widened 180% from FY 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Annuncio • Jan 31
MYCELX Technologies Corporation Provides Earnings Guidance for the Year 2022 MYCELX Technologies Corporation provided earnings guidance for the year 2022. The Company exceeded previous guidance by achieving 2022 revenue of ca.$10.0 million, EBITDA of ca. negative $2.5 million and a net loss of ca.$4.0 million due to an increase in activity in the final month of the year which included an emergency response deployment in Saudi Arabia, higher than expected year end media sales and an increased scope for a REGEN project that was completed in December. Price Target Changed • Nov 16
Price target decreased to UK£0.95 Down from UK£2.95, the current price target is provided by 1 analyst. New target price is 228% above last closing price of UK£0.29. Stock is down 63% over the past year. The company posted a net loss per share of US$0.073 last year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Non-Executive Chairman Tom Lamb was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Sep 27
First half 2022 earnings released: US$0.13 loss per share (vs US$0.022 profit in 1H 2021) First half 2022 results: US$0.13 loss per share (down from US$0.022 profit in 1H 2021). Revenue: US$3.70m (down 11% from 1H 2021). Net loss: US$2.88m (down US$3.32m from profit in 1H 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Annuncio • Sep 15
MYCELX Technologies Corporation Revises Revenue Guidance for the Fiscal Year 2022 MYCELX Technologies Corporation revised revenue guidance for the fiscal year 2022. For the period, company is revising its guidance and now expects 10% year-on-year revenue growth. Board Change • Aug 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Non-Executive Chairman Tom Lamb was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Annuncio • Jun 13
MYCELX Technologies Corporation, Annual General Meeting, Jul 13, 2022 MYCELX Technologies Corporation, Annual General Meeting, Jul 13, 2022, at 13:00 Coordinated Universal Time. Location: Canaccord Genuity, 88 Wood St, London EC2V 7QR London, United Kingdom Reported Earnings • May 18
Full year 2021 earnings released: US$0.073 loss per share (vs US$0.31 loss in FY 2020) Full year 2021 results: US$0.073 loss per share (up from US$0.31 loss in FY 2020). Revenue: US$8.48m (up 19% from FY 2020). Net loss: US$1.43m (loss narrowed 77% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings. Annuncio • Feb 11
MYCELX Technologies Corporation Provides Unaudited Earnings Guidance for the Year Ended December 31, 2021 and 2022 MYCELX Technologies Corporation provided unaudited earnings guidance for the year ended December 31, 2021. Anticipated unaudited 2021 revenue of $8.5 million (2020: $7.1 million).In 2022 the Company is targeting a similar level of year-on-year revenue growth but this remains subject to the timing of anticipated contract wins and renewals. Annuncio • Jan 26
MYCELX Technologies Corporation Announces Successful Trial of PFAS Remediation System MYCELX Technologies Corporation announced that it has successfully completed a trial in the United States of its PFAS remediation system which deploys its patented MYCELX technology. The results of the trial confirm the ability of MYCELX's PFAS remediation system to reduce contamination to non-detect level in a single pass through the system. As part of its continuing strategy to address the PFAS remediation market, MYCELX commenced an important trial at an industrial site in Newburgh, New York, in December 2021. The trial involved treating PFAS contaminated water from a storm water retention pond. The likely source of the PFAS contamination was aqueous film forming foams (AFFF). The presence of additional contaminants, such as glycols from plane de-icing procedures, ensured a challenging and complex water source to remediate. MYCELX installed a mobile trial system using the patented MYCELX technology for PFAS remediation. Earlier generations of this technology have already been successfully deployed in Australia, which is recognised as being at the forefront of PFAS remediation. The MYCELX solution is designed to offer a lower life-cycle cost of treatment, primarily due to significantly reduced waste versus alternative technologies. The trial successfully demonstrated the ability of the MYCELX system to completely remove all detected chemicals to non-detectable concentrations in a single pass, achieving a 99.99% removal efficiency. Complete removal of this spectrum of PFAS chemicals eliminates both regulated PFAS compounds, and complete removal will prevent future degradation of components into PFAS compounds that may be subject to future regulation. The technology provided a failsafe treatment with no rise in differential pressures or increase in outlet concentrations over the length of the trial. Reported Earnings • Oct 01
First half 2021 earnings released: EPS US$0.022 (vs US$0.14 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$4.16m (up 14% from 1H 2020). Net income: US$435.0k (up US$3.21m from 1H 2020). Profit margin: 10% (up from net loss in 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance. Executive Departure • Jul 13
Independent Non-Executive Chairman Timothy John Eggar has left the company On the 7th of July, Timothy John Eggar's tenure as Independent Non-Executive Chairman ended after 9.9 years in the role. We don't have any record of a personal shareholding under Timothy John's name. Timothy John is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 11.29 years. Reported Earnings • May 28
Full year 2020 earnings released: US$0.31 loss per share (vs US$0.15 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$7.10m (down 40% from FY 2019). Net loss: US$6.09m (loss widened 106% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Annuncio • May 15
MYCELX Technologies Corporation Announces the Validation and Capacity Upgrade of its PFAS system at an Australian Department of Defence location MYCELX Technologies Corporation announced the validation and capacity upgrade of its PFAS system at an Australian Department of Defence location. This follows a deployment of the PFAS system by the Australian partner in 2018. The capacity upgrade contract was awarded as a consequence of the robust operating performance demonstrated over a two-year period, within budget, as well as allowing the customer to both support, improve and adhere to, its environmental goals. PFAS (Perfluoroalkyl substances) remediation has been a key area of organic diversification for MYCELX and the Company is delighted with the progress made. This re-deployment is a step forward for the Company and has the potential to lead to further contract awards in due course. With the increasing awareness and legislation worldwide, the benefits of MYCELX's proprietary technology allows for efficient removal of toxic "forever" chemicals associated with adhesives and Teflon related products and has the potential to be a leading solution for PFAS remediation worldwide. Is New 90 Day High Low • Feb 04
New 90-day low: UK£0.23 The company is down 21% from its price of UK£0.29 on 05 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 7.0% over the same period. Is New 90 Day High Low • Jan 19
New 90-day low: UK£0.28 The company is down 2.0% from its price of UK£0.29 on 21 October 2020. The British market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 10.0% over the same period. Is New 90 Day High Low • Dec 30
New 90-day high: UK£0.33 The company is up 12% from its price of UK£0.29 on 01 October 2020. The British market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Commercial Services industry, which is up 9.0% over the same period. Is New 90 Day High Low • Sep 24
New 90-day low: UK£0.33 The company is down 30% from its price of UK£0.47 on 26 June 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is down 2.0% over the same period. Reported Earnings • Sep 23
First half earnings released Over the last 12 months the company has reported total losses of US$5.83m, with earnings decreasing by US$7.42m from the prior year. Total revenue was US$6.48m over the last 12 months, down 73% from the prior year. 
